News by community

30.06.2020 Cellestia Biotech article on PNAS “Pharmacological disruption of the Notch transcription factor complex”

Cellestia is a privately-owned clinical-stage biopharma company led by an experienced team of scientists, drug developers and business professionals. Cellestia is giving hope to cancer patients who have no other treatment or therapy options. The drug discovery platform, built on a unique mode of action and together with companion diagnostics, is a first-in-class solution for orphan cancers such as cancer of the salivary gland and childhood Leukaemia. At the same time, Cellestia iscontinuing to expand the portfolio through targeting large cancer indications such as breast and colorectal cancers.

” The acceptance of our peer reviewed manuscript in a prestigious journal such as PNAS validates the scientific foundation of Cellestia Biotech’s drug discovery platform. Building upon this science, Cellestia is expanding its pipeline of assets in different disease areas” says Rajwinder Lehal, Chief Scientific Officer at Cellestia Biotech AG.

> Read here the full PNAS article.